Medical management of primary hyperparathyroidism.
Primary hyperparathyroidism
conservative therapies
hypercalcemia
parathyroid hormone
Journal
Archives of endocrinology and metabolism
ISSN: 2359-4292
Titre abrégé: Arch Endocrinol Metab
Pays: Brazil
ID NLM: 101652058
Informations de publication
Date de publication:
11 Nov 2022
11 Nov 2022
Historique:
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
19
11
2022
Statut:
ppublish
Résumé
Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used pharmacological alternatives: bisphosphonates, denosumab, cinacalcet and hormone therapy, in addition to combined therapy. We also address the relevant aspects of perioperative management.
Identifiants
pubmed: 36382758
pii: 2359-3997000000558
doi: 10.20945/2359-3997000000558
pmc: PMC10118813
doi:
pii:
Substances chimiques
Cinacalcet
UAZ6V7728S
Parathyroid Hormone
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-693Références
J Bone Miner Res. 2001 Jan;16(1):113-9
pubmed: 11149474
J Clin Endocrinol Metab. 2004 Jul;89(7):3319-25
pubmed: 15240609
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8
pubmed: 21118827
Arch Intern Med. 2000 Jul 24;160(14):2161-6
pubmed: 10904459
Nat Rev Dis Primers. 2016 May 19;2:16033
pubmed: 27194212
F1000Res. 2016 Jan 04;5:
pubmed: 27508075
Clin Endocrinol (Oxf). 2014 Jun;80(6):797-803
pubmed: 24382124
Eur J Endocrinol. 2021 Aug 27;185(4):515-524
pubmed: 34324430
Endocrine. 2020 Sep;69(3):642-649
pubmed: 32621048
J Clin Endocrinol Metab. 2014 Oct;99(10):3580-94
pubmed: 25162667
J Bone Miner Metab. 2014 Mar;32(2):151-8
pubmed: 23700284
J Am Geriatr Soc. 2018 Mar;66(3):518-524
pubmed: 29364518
J Clin Endocrinol Metab. 2015 Sep;100(9):3443-51
pubmed: 26079779
Arq Bras Endocrinol Metabol. 2013 Aug;57(6):406-24
pubmed: 24030180
Endocrine. 2011 Jun;39(3):283-7
pubmed: 21445714
J Bone Miner Metab. 2022 Mar;40(2):292-300
pubmed: 34761302
Endocr Pract. 2009 Nov-Dec;15(7):705-13
pubmed: 19625240
Int J Endocrinol. 2011;2011:415719
pubmed: 21461394
Surgery. 2020 Jan;167(1):144-148
pubmed: 31582307
J Clin Endocrinol Metab. 2009 Aug;94(8):2766-72
pubmed: 19470620
J Clin Endocrinol Metab. 2003 Feb;88(2):581-7
pubmed: 12574184
Arch Endocrinol Metab. 2021 Oct 29;65(5):669-673
pubmed: 34591412
J Clin Endocrinol Metab. 2003 Mar;88(3):1174-8
pubmed: 12629102
J Clin Endocrinol Metab. 2014 Oct;99(10):3561-9
pubmed: 25162665
Endocr Pract. 2011 Mar-Apr;17(2):226-34
pubmed: 21041169
Rev Bras Reumatol. 2011 Mar-Apr;51(2):131-7
pubmed: 21584419
J Clin Endocrinol Metab. 2005 Jan;90(1):135-41
pubmed: 15522938
Osteoporos Int. 2017 Jan;28(1):1-19
pubmed: 27613721
Lancet. 2018 Jan 13;391(10116):168-178
pubmed: 28923463
Eur J Endocrinol. 2015 May;172(5):527-35
pubmed: 25637076
J Clin Endocrinol Metab. 2009 Dec;94(12):4860-7
pubmed: 19837909
Ann Intern Med. 1996 Sep 1;125(5):360-8
pubmed: 8702086
Ann Clin Biochem. 2015 Jul;52(Pt 4):462-9
pubmed: 25468998
Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):593-607
pubmed: 30449543
J Clin Densitom. 2013 Jan-Mar;16(1):33-9
pubmed: 23374739
Lancet Diabetes Endocrinol. 2020 May;8(5):407-417
pubmed: 32333877